The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here:

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Åke Borg

Åke Borg

Principal investigator

Åke Borg

Targeted sequencing of BRCA1 and BRCA2 across a large unselected breast cancer cohort suggests that one-third of mutations are somatic


  • C Winter
  • M P Nilsson
  • E Olsson
  • A M George
  • Y Chen
  • A Kvist
  • T Törngren
  • J Vallon-Christersson
  • C Hegardt
  • J Häkkinen
  • G Jönsson
  • D Grabau
  • M Malmberg
  • U Kristoffersson
  • M Rehn
  • S K Gruvberger-Saal
  • C Larsson
  • Å Borg
  • N Loman
  • L H Saal

Summary, in English

BACKGROUND: A mutation found in the BRCA1 or BRCA2 gene of a breast tumor could be either germline or somatically acquired. The prevalence of somatic BRCA1/2 mutations and the ratio between somatic and germline BRCA1/2 mutations in unselected breast cancer patients are currently unclear.

PATIENTS AND METHODS: Paired normal and tumor DNA was analyzed for BRCA1/2 mutations by massively parallel sequencing in an unselected cohort of 273 breast cancer patients from south Sweden.

RESULTS: Deleterious germline mutations in BRCA1 (n = 10) or BRCA2 (n = 10) were detected in 20 patients (7%). Deleterious somatic mutations in BRCA1 (n = 4) or BRCA2 (n = 5) were detected in 9 patients (3%). Accordingly, about 1 in 9 breast carcinomas (11%) in our cohort harbor a BRCA1/2 mutation. For each gene, the tumor phenotypes were very similar regardless of the mutation being germline or somatically acquired, whereas the tumor phenotypes differed significantly between wild-type and mutated cases. For age at diagnosis, the patients with somatic BRCA1/2 mutations resembled the wild-type patients (median age at diagnosis, germline BRCA1: 41.5 years; germline BRCA2: 49.5 years; somatic BRCA1/2: 65 years; wild-type BRCA1/2: 62.5 years).

CONCLUSIONS: In a population without strong germline founder mutations, the likelihood of a BRCA1/2 mutation found in a breast carcinoma being somatic was ∼1/3 and germline 2/3. This may have implications for treatment and genetic counseling.


  • Breastcancer-genetics
  • Tumor microenvironment
  • Create Health
  • Lund Melanoma Study Group
  • BioCARE: Biomarkers in Cancer Medicine improving Health Care, Education and Innovation
  • Surgery (Lund)
  • Clinical Sciences, Helsingborg
  • Division of Clinical Genetics
  • Surgery
  • Division of Translational Cancer Research

Publishing year







Annals of Oncology





Document type

Journal article


Oxford University Press


  • Cancer and Oncology




  • Sweden Cancerome Analysis Network - Breast (SCAN-B): a large-scale multicenter infrastructure towards implementation of breast cancer genomic analyses in the clinical routine

Research group

  • Lund Melanoma Study Group
  • Surgery


  • ISSN: 1569-8041